Cohen & Steers (CNS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 Apr, 2026Executive summary
Annual Meeting scheduled for April 30, 2026, with voting on director nominees and other proxy proposals.
Board recommends voting "For" all director nominees, including those opposed by ISS.
ISS raised concerns about compensation and benefits for certain directors, but the Board provides detailed rebuttals.
Voting matters and shareholder proposals
Shareholders are asked to vote on the election of nine director nominees.
ISS recommended against several Independent Director Nominees due to compensation concerns.
Board urges support for all nominees, emphasizing the rationale for compensation decisions.
No changes to the proxy card or voting instructions; previously cast votes remain valid unless changed.
Board of directors and corporate governance
Independent Director Nominees serve on the Nominating and Corporate Governance Committee, overseeing director compensation.
Board clarifies that medical benefits for Mr. Cohen are legacy provisions with modest cost.
Board asserts responsible oversight of director compensation and alignment with shareholder interests.
Latest events from Cohen & Steers
- AUM hit $93.1B with strong inflows, robust EPS, and resilient margins amid market risks.CNS
Q1 202617 Apr 2026 - Annual meeting to vote on directors, auditor, and executive pay; strong board diversity and oversight.CNS
Proxy filing20 Mar 2026 - AUM hit $80.7B with strong performance, improved liquidity, and resilient margins despite outflows.CNS
Q2 20243 Feb 2026 - AUM hit $90.5B with strong inflows, robust results, and accelerating ETF adoption in 2025.CNS
Q4 20251 Feb 2026 - AUM hit $91.8B in Q3 2024, with strong inflows, investment gains, and margin improvement.CNS
Q3 202419 Jan 2026 - Q4 EPS was $0.89, AUM $85.8B, with $860M net inflows and new ETFs set for Q1 2025.CNS
Q4 20249 Jan 2026 - AUM and net inflows rose, but EPS and revenue fell; new ETFs and a $0.62 dividend announced.CNS
Q1 202525 Dec 2025 - Board recommends approval of all annual meeting items, with strong governance and pay-for-performance.CNS
Proxy Filing1 Dec 2025 - Revenue, net income, and AUM rose in Q2, with strong investment performance and new launches.CNS
Q2 202513 Nov 2025